Levels of cardiac biomarkers (troponin T and NT-proBNP) are known to be constantly elevated in patients with cardiac amyloidosis [123], and a decreased myocardial perfusion may contribute to these increases. This evidence concerns the gene NPPB and cardiac amyloidosis.